Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes

We’re working to meet the needs of health care practitioners and their patients

Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutions that address unmet medical needs and improve clinical results.

Pacira Core Values

We are a team of dedicated and highly talented professionals focused on driving improved patient outcomes with opioid-reducing strategies. We are an organization built on high ethical standards, an unwavering commitment to patients, and transparent communications. We have a drive and a desire to improve the world around us and make a meaningful difference in the lives of patients, families, communities, and society.

Patient safety and welfare are our top priority at all times.

Our people are our greatest asset.

We are passionate about what we do.

Our thoughts are shared generously.

Building trust is essential.

Teamwork is the cornerstone of our business success.

Dedicated Leadership

Our management team has unparalleled experience in the hospital and ambulatory surgical center marketplace and a track record of successfully commercializing products. This experience helps us to ensure that Pacira products, pipeline programs, and partnerships in the marketplace are consistently of the highest quality. As a public company (NASDAQ: PCRX), we hold our shareholders in the same high regard as we do the physicians and patients we serve.

Frank Lee

Frank D. Lee

Chief Executive Officer and Director

Mr. Lee joined Pacira as Chief Executive Officer and member of the Board of Directors in January 2024. An accomplished biopharmaceutical leader, Mr. Lee brings thirty years of global experience and a strong track record of product development and commercial success across both small biotech and large pharmaceutical organizations. He most recently served as Chief Executive Officer and member of the Board of Directors of publicly traded Forma Therapeutics from March 2019 until its acquisition by Novo Nordisk in October 2022. During his tenure at Forma, Mr. Lee transformed the organization from an early-stage drug discovery company into one focused on the clinical development of lead assets in rare hematologic disorders and cancer. Prior to Forma, Mr. Lee served as Senior Vice President, Global Product Strategy and Therapeutic Area Head for Immunology, Ophthalmology and Infectious Diseases at Genentech, a member of the Roche Group. He was responsible for driving the global development and commercialization strategy for the late-stage portfolio, and for global portfolio product sales of $11 billion. Mr. Lee’s 13-year tenure at Genentech included leadership positions of increasing scope and responsibility focused on delivering transformative medicines to patients and driving the growth of multiple in oncology, immunology and ophthalmology products to blockbuster/multi-blockbuster status. Prior to Genentech, Mr. Lee spent approximately 13 years across Novartis, Janssen and Eli Lilly. He received a Bachelor of Science degree in Chemical Engineering from Vanderbilt University and an MBA from the Wharton Graduate School of Business. Mr. Lee currently serves as Chairman of Catamaran Bio, Executive Chairman of Therini Bio, Director of Bolt Biotherapeutics and Advisor to Lightstone Ventures.

daryl

Daryl Gaugler

Chief Operating Officer

Daryl Gaugler is Chief Operating Officer at Pacira, responsible for overseeing Sales, Commercial Operations, Reimbursement, Sports Accounts, Health System Alliance, Learning and Development, and Marketing and Communications. He previously served as Senior Vice President of Commercial Operations, a role he held at the company since June 2019. Prior to joining Pacira, Mr. Gaugler spent over 20 years with the Quintiles Transnational organization (now IQVIA), most recently as President of North American Commercial Solutions. Mr. Gaugler delivered significant revenue and profit growth while leading customer satisfaction and employee engagement within the organization. He is a seasoned life sciences executive with 30 years of experience in commercial leadership that includes building and directing over 400 commercial teams and designing go-to-market strategies for more than 20 companies. Mr. Gaugler holds a Bachelor of Science in Business Administration from Shippensburg University.

Photo of Max Reinhardt

Max Reinhardt

President, Rest of World

Max Reinhardt joined Pacira in June 2019 and serves as President, Rest of World. In this capacity Mr. Reinhardt oversees global commercialization efforts for the Pacira portfolio, as well as the company’s payer and employer relations activities and key customer partnerships. Mr. Reinhardt has twenty-five years of medical device experience and has held positions of increasing responsibility in sales, marketing and general management. Most recently he served as Vice President, Marketing at DePuy Synthes, where he led the negotiations and launch of the Pacira alliance to bring EXPAREL® to orthopedic customers nationwide. Prior to this role, Mr. Reinhardt served in several capacities at Johnson & Johnson including Director of Sales and Marketing for DePuy Spine in 2002, where he led the UK spine business before relocating to the US as Vice President of US Sales for DePuy Spine in 2006. In 2011 he was named Vice President, Worldwide Marketing, a position in which he played a key role in the acquisition and integration of Synthes Spine. In 2012 he was named Worldwide President, DePuy Synthes Spine, and led the spine business through the first two years of integration. Mr. Reinhardt was also responsible for the DePuy Synthes Joint Reconstruction, Mitek Sports Medicine, Early Intervention and the Power Tools divisions between 2015 and 2016. Prior to his time at Johnson & Johnson, Mr. Reinhardt served in sales leadership roles at both Olympus KeyMed and STERIS Corporation in the UK.

Mr. Reinhardt earned his Higher National Diploma at Sparsholt College of Agriculture in the UK and his Master of Science degree in marketing from the University of Hull, England.

Photo of Kristen Williams, JD

Kristen Williams, JD

Chief Administrative Officer and Secretary

Kristen Williams worked with the company as a legal consultant before joining as Corporate Counsel in December 2011. Since then, she has been promoted to Vice President, General Counsel in 2013 and to Chief Administrative Officer, General Counsel and Secretary in 2014. Prior to joining Pacira, she was Vice President, Corporate Compliance and Assistant General Counsel for Bioenvision, Inc from June 2004 until its merger with Genzyme Corporation in 2007. From September 1999 to June 2004, she practiced corporate law at Paul Hastings LLP in New York, where her practice encompassed all aspects of public and private mergers and acquisitions, corporate finance, and securities law and compliance, with a core focus in the healthcare industry.

Ms. Williams earned a Bachelor of Science Degree in Business Administration from Bucknell University and a J.D. Degree from the University of Denver, College of Law in Denver, CO.

Jonathan Slonin

Jonathan Slonin, MD

Chief Medical Officer

Dr. Jonathan Slonin joined Pacira in 2020 and most recently served as Chief Clinical Officer, directing the Company’s customer-facing medical operations and iovera device franchise. As Chief Medical Officer, Dr. Slonin will oversee research and development and all customer-facing medical operations in addition to clinical, R&D, and medical strategy. He brings over 15 years of experience to Pacira as a board-certified anesthesiologist who has held numerous clinical and leadership positions with TeamHealth and Envision Healthcare including Regional Medical Director for the Southeast with TeamHealth and Chairman of Anesthesiology for the Cleveland Clinic Martin Health. Dr. Slonin received his Bachelor of Science in Biomedical Engineering and his MD degree from the University of Miami. He completed his anesthesiology residency at University of Miami/Jackson Memorial Hospital where he served as chief resident. Dr. Slonin received his MBA degree from George Washington University.

ron

Ron Ellis, DO

Chief Strategy Officer

Ron Ellis joined Pacira in 2016 and currently serves as Chief Strategy Officer. In this role he oversees Corporate Strategy, Business Development, and New Product Planning. Prior to joining Pacira, Dr. Ellis was a Managing Partner at Leerink Partners (acquired by Silicon Valley Bank), a healthcare investment firm advising institutional investors on capital markets and partnering with innovation companies throughout their financial lifecycle. He previously held positions as a Healthcare Trading Specialist at Citigroup Global Markets and Deutsche Bank Securities, and a Biotechnology Analyst in Equity Research at Prudential Securities and Leerink Swann. Dr. Ellis is a Director of GeneQuine Biotherapeutics, a private adenovirus gene therapy company focused on disease-modifying solutions for musculoskeletal conditions, and CarthroniX, a private immuno-oncology start-up with its lead compound in development for osteoarthritis. He also serves as a Board Observer at Spine BioPharma, a private company advancing non-surgical, non-opioid therapies for degenerative disc disease; and Genascence, a private adeno-associated virus gene therapy company in clinical development for osteoarthritis. He earned his medical degree from the Philadelphia College of Osteopathic Medicine and holds a Master of Business Administration from St. Joseph’s University.

Photo of Charles A. Reinhart III

Charles A. Reinhart III

Chief Financial Officer

In 2016, Charles A. Reinhart III joined Pacira as Chief Financial Officer, responsible for overseeing all financial and capital market activities at Pacira, including accounting, financial reporting, financial planning and analysis, and investor relations.

Prior to joining Pacira, Mr. Reinhart served as Chief Financial Officer of Covis Pharmaceuticals, Inc. From September 2011 to August 2014, he served as Executive Vice President and Chief Financial Officer of Archimedes Pharma Ltd. Mr. Reinhart also served as Senior Vice President and Chief Financial Officer of PharmAthene, Inc., a biodefense company engaged in the development of next generation medical countermeasures against biological and chemical threats, from 2009 to 2011. He has also held senior financial roles at Millennium Pharmaceuticals, Inc., Cephalon, Inc. and several early-stage life sciences companies. He also served as a director of Osiris Therapeutics, Inc. (Nasdaq: OSIR) from September 2018 until it was acquired in April 2019. Mr. Reinhart has successfully built and managed finance organizations within rapidly growing companies, responsible for accounting and financial reporting, financial planning and analysis, tax, treasury, risk management and procurement. He has worked closely with commercial teams to evaluate sales operations, monitor product pricing and implement contracting strategies. In addition, he has significant experience in investor relations, corporate development and capital raising. He has been integrally involved in equity and debt financing transactions, as well as the evaluation, acquisition and integration of multiple products and companies.

Mr. Reinhart earned his Bachelor of Science degree from Lehigh University and his MBA from the Wharton School of the University of Pennsylvania. He is also a CPA.

Christopher

Christopher Young

Chief Manufacturing Officer

Christopher Young joined Pacira in 2023 and currently serves as Chief Manufacturing Officer. In this role he oversees all manufacturing activities across the Pacira product portfolio including supply chain design, product life cycle management, demand and requirements planning, capacity, and product launches across all global manufacturing locations. Prior to joining Pacira, Chris served as Executive Vice President, Global Operations at Akorn Inc, where he oversaw manufacturing at four global sites and directed global operations, procurement, supply chain, technical services, engineering, security, and distribution. Previous to his tenure at Akorn, Chris spent five years as Executive Vice President, Global Operations at Alvogen Inc with similar responsibilities including managing employees, operations and capital budgets at five manufacturing sites, directing technical transfer, and operational excellence in support of $1 billion in sales worldwide. Chris has also held positions of increasing responsibility at Actavis/Alpharma/Purepac Pharmaceutical Co, Zenith Goldline Pharmaceuticals, and Copley Pharmaceutical, Inc. He holds a Bachelor of Science degree from Gettysburg College and a Master of Business Administration degree from Rutgers University.

Molloy

Anthony Molloy III, Esq.

Chief Legal and Compliance Officer

Anthony Molloy started as Associate General Counsel in December 2013. Since then, he has been promoted to Vice President, General Counsel in 2016 and to Senior Vice President, General Counsel and Deputy Compliance Officer in 2021. A licensed patent attorney, prior to joining Pacira, he practiced IP law and litigated at Patton Boggs LLP in Newark, NJ from April 2006 to November 2013. From 1998 to 2004, prior to law school, Mr. Molloy worked as a Chemical Engineer specializing in polymer chemistry in the R&D group of The Okonite Company.

Mr. Molloy earned a Bachelor of Arts Degree in Chemistry from SUNY Geneseo, a Bachelor of Science Degree in Chemical Engineering from SUNY Buffalo, a Masters Degree in Technology Management from Stevens Institute of Technology, and his J.D. Degree from Rutgers Law School - Newark.

Photo of Dennis Mcloughlin

Dennis McLoughlin

Chief Customer Officer

Dennis McLoughlin serves as Chief Customer Officer at Pacira. Mr. McLoughlin joined Pacira in 2014 as part of the sales leadership team, overseeing several components of the business while fulfilling multiple roles including Chief Commercial Officer, Senior Vice President and Executive Director, Alliance Management. From December 2013 to January 2017, Mr. McLoughlin served as an Area Sales Director. With more than 20 years of pharmaceutical industry expertise, Mr. McLoughlin has extensive background in sales, marketing, managed markets, and strategic commercial operations.

Prior to joining Pacira, he was the President and a Principal of Remedy Group, a company with expertise in all phases of commercial operations, business development and corporate alliances for the pharmaceutical, life sciences and healthcare industries. Mr. McLoughlin has held various management positions in sales, national accounts, training, product marketing, and business development for GlaxoSmithKline and Organon Pharmaceuticals (now Merck). He earned his Bachelor of Science in Marketing from St. Joseph’s University in Philadelphia, Pennsylvania.